News coverage about Summit Therapeutics PLC (NASDAQ:SMMT) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Summit Therapeutics PLC earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.1210808671624 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Summit Therapeutics PLC (NASDAQ SMMT) opened at 12.62 on Friday. The firm has a 50-day moving average price of $12.89 and a 200-day moving average price of $11.96. Summit Therapeutics PLC has a 52-week low of $5.31 and a 52-week high of $19.75. The company’s market cap is $156.25 million.

A number of research firms recently commented on SMMT. ValuEngine raised Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Canaccord Genuity reaffirmed a “buy” rating and issued a $28.00 price target on shares of Summit Therapeutics PLC in a research note on Friday, June 16th. Oppenheimer Holdings, Inc. set a $24.00 price target on Summit Therapeutics PLC and gave the company a “buy” rating in a research note on Thursday, June 22nd. Finally, Zacks Investment Research raised Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday, July 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Summit Therapeutics PLC presently has a consensus rating of “Buy” and an average target price of $25.00.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Summit Therapeutics PLC (SMMT) Share Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/26/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-summit-therapeutics-plc-smmt-share-price.html.

About Summit Therapeutics PLC

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Insider Buying and Selling by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.